Abstract
Understanding the immune response to Middle East respiratory syndrome coronavirus (MERS-CoV) is crucial for disease prevention and vaccine development. We studied the antibody responses in 48 human MERS-CoV infection survivors who had variable disease severity in Saudi Arabia. MERS-CoV–specific neutralizing antibodies were detected for 6 years postinfection.
Highlights
Three novel human coronaviruses have caused different worldwide outbreaks that had variable disease severity and geographic distribution: severe acute respiratory syndrome coronavirus (SARS-CoV) during 2003; Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) during 2012; and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused coronavirus disease starting in 2019 [1]
A limited number of studies have evaluated the longevity of MERS antibody responses
Choe et al showed that patients who had severe disease had robust MERS-CoV neutralizing antibody titers for 1 year, and patients who had mild disease had waning antibody response over time [5]
Summary
We studied the antibody responses in 48 human MERS-CoV infection survivors who had variable disease severity in Saudi Arabia. Author affiliations: King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia Wang); King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia Alfaraj); Security Forces Hospital, Makkah, Saudi Arabia (W.A. Ahmed); King Fahad Medical City, Riyadh (M.A. Enani); Prince Sultan Military Medical City, Riyadh Haseeb); King Abdulaziz University, Jeddah (S.A. El-Kafrawy, A.M. Hassan); King Fahd Medical Research Center, Jeddah (E.F. Azhar); University of Iowa, Iowa City, Iowa, USA We assessed antibody responses in 48 MERS survivors who had variable disease severity and duration
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call